{"id":4644,"date":"2025-05-25T18:44:15","date_gmt":"2025-05-25T18:44:15","guid":{"rendered":"https:\/\/neoplas-med.eu\/en\/?p=4644"},"modified":"2025-05-25T18:44:15","modified_gmt":"2025-05-25T18:44:15","slug":"japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med","status":"publish","type":"post","link":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/","title":{"rendered":"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-4579\" src=\"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg\" alt=\"\" width=\"2080\" height=\"1387\" srcset=\"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg 2080w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-768x512.jpg 768w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-1536x1024.jpg 1536w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-2048x1366.jpg 2048w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-1400x934.jpg 1400w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-600x400.jpg 600w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-750x500.jpg 750w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-500x333.jpg 500w, https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699-1320x880.jpg 1320w\" sizes=\"auto, (max-width: 706px) 89vw, (max-width: 767px) 82vw, 740px\" \/><\/p>\n<ul>\n<li><strong data-start=\"56\" data-end=\"181\">Capital Increase Brings Additional \u20ac17 Million for International Marketing and Further Development of Technology Platform<\/strong><\/li>\n<li><strong data-start=\"184\" data-end=\"306\">German High-Tech Solution Sets New Standard in the Treatment of Infected and Chronic Wounds \u2013 50% Faster Wound Healing<\/strong><\/li>\n<\/ul>\n<p data-start=\"308\" data-end=\"1031\"><strong data-start=\"308\" data-end=\"341\">Greifswald, November 19, 2024<\/strong> \u2013 Greifswald-based plasma medical technology pioneer <strong data-start=\"395\" data-end=\"415\">Neoplas Med GmbH<\/strong> is deepening its strategic collaboration with Japanese technology group <strong data-start=\"488\" data-end=\"499\">Niterra<\/strong>. As part of a capital increase, <strong data-start=\"532\" data-end=\"566\">Niterra Ventures Company (NVC)<\/strong> has increased its stake in Neoplas Med to approximately 49%, marking a strong signal of a long-term partnership. The company, which originated from the Leibniz Institute for Plasma Science and Technology (INP), will receive around \u20ac17 million through this investment. NVC had already invested in Neoplas Med in 2022 and 2023 to jointly develop the market for innovative medical technology products. In total, NVC has now invested around \u20ac24 million in Neoplas Med.<\/p>\n<p data-start=\"1033\" data-end=\"1846\">The core product of Neoplas Med is the <strong data-start=\"1072\" data-end=\"1110\">argon cold plasma jet, kINPen\u00ae MED<\/strong>, an innovative &#8220;plasma pen&#8221; that directs a precise plasma beam onto wounds and significantly accelerates healing. Clinical studies show that treatment time can be reduced by 50% compared to conventional methods \u2013 without side effects or the development of resistance. Neoplas Med is one of the few companies using the noble gas argon to generate cold plasma for its nearly painless and rapid plasma jet therapy. Peer-reviewed studies published in renowned scientific journals have demonstrated the effectiveness in treating both infected and chronic wounds. Neoplas Med GmbH is currently the <strong data-start=\"1703\" data-end=\"1758\">only manufacturer of cold plasma products in Europe<\/strong> that meets the strict requirements of the European <strong data-start=\"1810\" data-end=\"1845\">Medical Device Regulation (MDR)<\/strong>.<\/p>\n<p data-start=\"1848\" data-end=\"2116\">In Germany, 75% of university hospitals as well as numerous doctors\u2019 offices and clinics use Neoplas Med\u2019s patented <strong data-start=\"1964\" data-end=\"1997\">argon jet cold plasma therapy<\/strong>. More than 500,000 treatments have already been performed worldwide \u2013 including in leading clinics in the Middle East.<\/p>\n<p data-start=\"2118\" data-end=\"2525\">Neoplas Med was recently recognized as a <strong data-start=\"2159\" data-end=\"2208\">\u201clighthouse company in the healthcare sector\u201d<\/strong> by Manuela Schwesig, Minister-President of the German state of Mecklenburg-Western Pomerania. As a young company, Neoplas Med benefits from ideal conditions for development, production, and growth within the plasma medicine research cluster in Greifswald. By the end of the year, Neoplas Med will employ 30 people.<\/p>\n<p>&#8220;The additional investment from NVC opens up entirely new opportunities for us to access international markets, expand our technology platform, and develop new products. This is not only a major step forward but also helps secure and create new jobs in the high-tech sector here in Mecklenburg-Western Pomerania,&#8221; says Ulrike Sailer, CEO of Neoplas Med.<\/p>\n<p>Dirk Schapeler, President of Niterra Ventures Company, adds: &#8220;We are expanding into new business areas in medicine, cleantech, energy, and the Internet of Things (IoT) to improve quality of life through advanced technologies. We\u2019ve worked closely with Neoplas Med in recent years and are impressed by the treatment outcomes. This follow-on investment was therefore a logical step.&#8221;<\/p>\n<p data-start=\"3280\" data-end=\"3570\">By 2030, Niterra aims to restructure its portfolio by increasing the share of business outside the automotive sector. In the medical field, the company is investing in technologies for the diagnosis and treatment of cardiovascular diseases, cancer, neurological disorders, and hypertension.<\/p>\n<h3 data-start=\"3577\" data-end=\"3607\"><strong data-start=\"3581\" data-end=\"3607\">About Neoplas Med GmbH<\/strong><\/h3>\n<p data-start=\"3609\" data-end=\"3902\">Approximately <strong data-start=\"3623\" data-end=\"3699\">two million people in Germany suffer from serious wound-related diseases<\/strong>. Neoplas Med GmbH is advancing the <strong data-start=\"3735\" data-end=\"3792\">clinical application of argon cold plasma jet therapy<\/strong>, working to sustainably and effectively improve the quality of life for people with acute and chronic wounds.<\/p>\n<p data-start=\"3904\" data-end=\"4242\"><strong data-start=\"3904\" data-end=\"3924\">Argon jet plasma<\/strong> has antibacterial and wound-healing effects. The <strong data-start=\"3974\" data-end=\"3989\">kINPen\u00ae MED<\/strong> is the <strong data-start=\"3997\" data-end=\"4047\">world\u2019s first cold plasma jet powered by argon<\/strong>. It enables effective and gentle wound treatment with maximum precision and consistent treatment quality \u2013 without observed side effects or resistance development, up to potential wound closure.<\/p>\n<p data-start=\"4244\" data-end=\"4806\">To ensure that the new cold plasma jet therapy is reimbursed by health insurance providers, <strong data-start=\"4336\" data-end=\"4411\">Neoplas Med submitted an application for a clinical trial in April 2021<\/strong>, which was approved by the <strong data-start=\"4439\" data-end=\"4473\">Federal Joint Committee (G-BA)<\/strong> in February 2023. Recently, the <strong data-start=\"4506\" data-end=\"4577\">National Association of Statutory Health Insurance Physicians (KBV)<\/strong> published the decision of the Extended Evaluation Committee regarding the reimbursement for service providers involved in the study &#8220;Cold Plasma for Chronic Wounds.&#8221; The decision is currently under formal and substantive review. Neoplas Med\u2019s <strong data-start=\"4822\" data-end=\"4901\">strategic partner for international expansion and technological advancement<\/strong> is the <strong data-start=\"4909\" data-end=\"4961\">Japanese high-tech corporation Niterra Co., Ltd.<\/strong><\/p>\n<h3 data-start=\"4968\" data-end=\"4999\"><strong data-start=\"4972\" data-end=\"4999\">About Niterra Co., Ltd.<\/strong><\/h3>\n<p data-start=\"5001\" data-end=\"5603\">Founded in <strong data-start=\"5012\" data-end=\"5038\">Nagoya, Japan, in 1936<\/strong>, <strong data-start=\"5040\" data-end=\"5061\">Niterra Co., Ltd.<\/strong> (formerly <strong data-start=\"5072\" data-end=\"5100\">NGK Spark Plug Co., Ltd.<\/strong>) is best known for its <strong data-start=\"5124\" data-end=\"5151\">NGK-branded spark plugs<\/strong> and <strong data-start=\"5156\" data-end=\"5188\">NTK-branded ceramic products<\/strong>. The brand name <strong data-start=\"5205\" data-end=\"5216\">Niterra<\/strong>, a fusion of the Latin words <em data-start=\"5246\" data-end=\"5255\">\u201cniteo\u201d<\/em> (shine) and <em data-start=\"5268\" data-end=\"5277\">\u201cterra\u201d<\/em> (earth), was introduced in <strong data-start=\"5305\" data-end=\"5319\">April 2023<\/strong> to reflect the company&#8217;s commitment to sustainability and its evolving portfolio focused on ceramics and beyond. Under the corporate motto <strong data-start=\"5459\" data-end=\"5483\">\u201cIGNITE YOUR SPIRIT\u201d<\/strong>, Niterra is expanding into the growth sectors of <strong data-start=\"5533\" data-end=\"5600\">mobility, healthcare, environment and energy, and communication<\/strong>.<\/p>\n<p data-start=\"5605\" data-end=\"5900\">The company recorded consolidated sales of approximately <strong data-start=\"5662\" data-end=\"5676\">\u20ac4 billion<\/strong> in the 2022 fiscal year (ending March 2023), operates <strong data-start=\"5731\" data-end=\"5756\">33 locations in Japan<\/strong> and <strong data-start=\"5761\" data-end=\"5783\">59 internationally<\/strong>, and employs over <strong data-start=\"5802\" data-end=\"5819\">16,000 people<\/strong>.<br data-start=\"5820\" data-end=\"5823\" \/>More at: <a class=\"\" href=\"https:\/\/www.ngkntk.co.jp\/english\" target=\"_new\" rel=\"noopener\" data-start=\"5832\" data-end=\"5900\">https:\/\/www.ngkntk.co.jp\/english<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Capital Increase Brings Additional \u20ac17 Million for International Marketing and Further Development of Technology Platform German High-Tech Solution Sets New Standard in the Treatment of Infected and Chronic Wounds \u2013 50% Faster Wound Healing Greifswald, November 19, 2024 \u2013 Greifswald-based plasma medical technology pioneer Neoplas Med GmbH is deepening its strategic collaboration with Japanese technology &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med&#8221;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-4644","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med - neoplas med GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med - neoplas med GmbH\" \/>\n<meta property=\"og:description\" content=\"Capital Increase Brings Additional \u20ac17 Million for International Marketing and Further Development of Technology Platform German High-Tech Solution Sets New Standard in the Treatment of Infected and Chronic Wounds \u2013 50% Faster Wound Healing Greifswald, November 19, 2024 \u2013 Greifswald-based plasma medical technology pioneer Neoplas Med GmbH is deepening its strategic collaboration with Japanese technology &hellip; Continue reading &quot;Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/\" \/>\n<meta property=\"og:site_name\" content=\"neoplas med GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-25T18:44:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2080\" \/>\n\t<meta property=\"og:image:height\" content=\"1387\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"kjurke\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"kjurke\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/\"},\"author\":{\"name\":\"kjurke\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/person\\\/e8b95ac434ef035faeed506d5c095277\"},\"headline\":\"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med\",\"datePublished\":\"2025-05-25T18:44:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/\"},\"wordCount\":825,\"publisher\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2023\\\/04\\\/4B1A8699.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/\",\"name\":\"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med - neoplas med GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2023\\\/04\\\/4B1A8699.jpg\",\"datePublished\":\"2025-05-25T18:44:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2023\\\/04\\\/4B1A8699.jpg\",\"contentUrl\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2023\\\/04\\\/4B1A8699.jpg\",\"width\":2080,\"height\":1387},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/\",\"name\":\"neoplas med GmbH\",\"description\":\"Die neoplas med GmbH entwickelt Medizintechnik f\u00fcr den Einsatz physikalischen Kaltplasmas f\u00fcr mehr Lebensqualit\u00e4t.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#organization\",\"name\":\"neoplas med GmbH\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/12\\\/cropped-logoNuMed.png\",\"contentUrl\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/12\\\/cropped-logoNuMed.png\",\"width\":588,\"height\":250,\"caption\":\"neoplas med GmbH\"},\"image\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/person\\\/e8b95ac434ef035faeed506d5c095277\",\"name\":\"kjurke\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/author\\\/kjurke\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med - neoplas med GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/","og_locale":"en_US","og_type":"article","og_title":"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med - neoplas med GmbH","og_description":"Capital Increase Brings Additional \u20ac17 Million for International Marketing and Further Development of Technology Platform German High-Tech Solution Sets New Standard in the Treatment of Infected and Chronic Wounds \u2013 50% Faster Wound Healing Greifswald, November 19, 2024 \u2013 Greifswald-based plasma medical technology pioneer Neoplas Med GmbH is deepening its strategic collaboration with Japanese technology &hellip; Continue reading \"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med\"","og_url":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/","og_site_name":"neoplas med GmbH","article_published_time":"2025-05-25T18:44:15+00:00","og_image":[{"width":2080,"height":1387,"url":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg","type":"image\/jpeg"}],"author":"kjurke","twitter_card":"summary_large_image","twitter_misc":{"Written by":"kjurke","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#article","isPartOf":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/"},"author":{"name":"kjurke","@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/person\/e8b95ac434ef035faeed506d5c095277"},"headline":"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med","datePublished":"2025-05-25T18:44:15+00:00","mainEntityOfPage":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/"},"wordCount":825,"publisher":{"@id":"https:\/\/neoplas-med.eu\/en\/#organization"},"image":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#primaryimage"},"thumbnailUrl":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg","articleSection":["Press Release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/","url":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/","name":"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med - neoplas med GmbH","isPartOf":{"@id":"https:\/\/neoplas-med.eu\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#primaryimage"},"image":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#primaryimage"},"thumbnailUrl":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg","datePublished":"2025-05-25T18:44:15+00:00","breadcrumb":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#primaryimage","url":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg","contentUrl":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/4B1A8699.jpg","width":2080,"height":1387},{"@type":"BreadcrumbList","@id":"https:\/\/neoplas-med.eu\/en\/news\/japanese-technology-group-niterra-increases-stake-in-german-med-tech-pioneer-neoplas-med\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoplas-med.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Japanese Technology Group Niterra Increases Stake in German Med-Tech Pioneer Neoplas Med"}]},{"@type":"WebSite","@id":"https:\/\/neoplas-med.eu\/en\/#website","url":"https:\/\/neoplas-med.eu\/en\/","name":"neoplas med GmbH","description":"Die neoplas med GmbH entwickelt Medizintechnik f\u00fcr den Einsatz physikalischen Kaltplasmas f\u00fcr mehr Lebensqualit\u00e4t.","publisher":{"@id":"https:\/\/neoplas-med.eu\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoplas-med.eu\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/neoplas-med.eu\/en\/#organization","name":"neoplas med GmbH","url":"https:\/\/neoplas-med.eu\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2021\/12\/cropped-logoNuMed.png","contentUrl":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2021\/12\/cropped-logoNuMed.png","width":588,"height":250,"caption":"neoplas med GmbH"},"image":{"@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/person\/e8b95ac434ef035faeed506d5c095277","name":"kjurke","url":"https:\/\/neoplas-med.eu\/en\/news\/author\/kjurke\/"}]}},"_links":{"self":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts\/4644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/comments?post=4644"}],"version-history":[{"count":4,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts\/4644\/revisions"}],"predecessor-version":[{"id":4648,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts\/4644\/revisions\/4648"}],"wp:attachment":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/media?parent=4644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/categories?post=4644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/tags?post=4644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}